SCHEMBL30451975

SCHEMBL30451975

COc1ccc(CNc2nnc(C3CC3)c3cc(Br)ccc23)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 16/20 0.44
CYP3A4 P08684 16/20 0.44
CYP2C19 P33261 16/20 0.44
TSHR P16473 14/20 0.44
CYP2D6 P10635 14/20 0.44
CYP2C9 P11712 11/20 0.44
ALDH1A1 P00352 10/20 0.44
HSD17B10 Q99714 9/20 0.44
CLK4 Q9HAZ1 7/20 0.44
MEN1 O00255 7/20 0.44
KMT2A Q03164 7/20 0.44
USP2 O75604 7/20 0.44
MAPK1 P28482 7/20 0.44
ALOX15 P16050 4/20 0.44
LMNA P02545 8/20 0.44
APLNR P35414 1/20 0.42
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HIF1A Q16665 4/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24252396 1.00 CYP1A2 (0.44) CYP1A2CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL24252738 0.84 MAPT (0.47) CYP1A2CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL30452114 0.84 MAPT (0.47) CYP1A2CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL30451398 0.82 CYP1A2 (0.52) CYP1A2CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL24252828 0.82 CYP1A2 (0.52) CYP1A2CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL24252778 0.81 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL30451795 0.81 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL24252814 0.80 CYP1A2 (0.49) CYP1A2CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL30451192 0.80 CYP1A2 (0.49) CYP1A2CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL24252397 0.78 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19TSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CYP1A2 2977/4885CYP3A4 2694/4885CYP2C19 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.